Joining us is lindsay bell i hear you, i think earnings seeing the twoweek bounce in the market, whats happening with expectations . We are seeing second half earnings, especially the Third Quarter numbers come down a little bit this is going to be after a Second Quarter where we see a decline of 1. 4 . Thats the expectation as we all know, earnings coming in better than expected. I would expect flat to up slightly in the Second Quarter but it is all about guidance as it always is because these tariffs the numbers havent been accounted for in the second half. Broad come a wakeup call it was. Theyre expecting 500 billion of imports to be tariffed by the end of the year so we wouldnt be surprised to see more companies to do that with us for the first hour of the story. Kayla tausche has the latest, meg terrell with the latest and phil lebeau at the Paris Air Show kayla . Theres hearing under way, a last roadblock to President Trump putting those new tariffs in place on the remaining chin
1800734cnbc or tweet me jim cramer the market will never go down enough to impress you, stocks will pull back for certain but only damaged merchandise look like opportunity the dow lost 112 point, s p sank 97 . Nasdaq down 2 . Youre looking for cheaper stocks of solid companies, not broken stocks of broke businesses so, when you have a really punishing day, but only a few good stocks have actually fallen far enough to become attractive, what the heck are you supposed to do . Ive got a set of disciplines im about to share with you that forces you to confront the nothings down enough, lame excuse for not taking action yes, i think its a lame excuse. Thats a probability on any different day youre going to get a full repeal based on earnings so thered be suddenly bargain ga look, you got really lucky. So let me give you cramers rules for selloffs during earning seasons. Earning seasons fault with a general list and its quite different than every day selloffs one of the calls i like to hear
Dec 19, 2020 at 7:45AM
Mercedes or Porsche? Steak or sushi? Two things can both be good but very different. For investors, the best coronavirus stock may depend on who s choosing. Breaking down the pros and cons of
BioNTech (NASDAQ:BNTX) reveals two very different companies linked by more than their partnership on a COVID-19 vaccine. So how do you choose between buying these two stocks, or do you really have to?
Image source: Getty Images.
What the future holds
Pfizer and BioNTech are at opposite ends of the spectrum in terms of corporate lifespans. As a $218 billion company founded 170 years ago, Pfizer is about as old as companies get. With 92 treatments in various stages of clinical trials and 49 individual drugs generating $52 billion in revenue, Pfizer is the definition of a blue-chip stock. Perhaps because those sales sit exactly where they were in 2013, the company has been transforming itself. The moves include merging Upjohn, its off-patent drug